- Home
- GSIW vs ITRM Comparison
GSIW vs ITRM Comparison
Compare GSIW & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSIW | ITRM |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | Hong Kong | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6M | 24.3M |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GSIW | ITRM |
|---|---|---|
| Price | $0.13 | $0.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 299.7K | ★ 704.7K |
| Earning Date | 01-01-0001 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,368,221.00 | $390,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $193.01 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 283.23 | N/A |
| 52 Week Low | $0.09 | $0.30 |
| 52 Week High | $1.79 | $2.10 |
Technical Indicators
Market Signals| Indicator | GSIW | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 39.19 | 26.17 |
| Support Level | $0.13 | $0.44 |
| Resistance Level | $0.14 | $0.37 |
| Average True Range (ATR) | 0.01 | 0.04 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 12.65 | 5.67 |
Price Performance
Historical ComparisonAbout GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.